MCID: OPT009
MIFTS: 55

Optic Neuritis

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Optic Neuritis

MalaCards integrated aliases for Optic Neuritis:

Name: Optic Neuritis 12 75 53 37 55 6 44 15 17 72 33

Classifications:



External Ids:

Disease Ontology 12 DOID:1210
KEGG 37 H01717
ICD9CM 35 377.3 377.30
MeSH 44 D009902
NCIt 50 C84950
SNOMED-CT 68 66760008
ICD10 33 H46 H46.9
UMLS 72 C0029134

Summaries for Optic Neuritis

KEGG : 37
Optic neuritis is a demyelinating inflammatory disease of the optic nerve that presents with an abrupt loss of vision. The majority of patients are between the ages of 20 and 50 years, with a mean age ranging from 30 to 35 years. It occurs more commonly in women than in men. The onset is usually with pain on eye movement in one eye and subacute visual loss. One-third of patients have a mildly edematous optic disc. The visual disturbance resolves in 95% of cases. Many cases of optic neuritis are associated with multiple sclerosis or neuromyelitis optica or can occur in isolation. Occasionally, optic neuritis can result from infectious processes involving the paranasal sinuses or occur in the course of a systemic viral infection. High-dosed intravenous methylprednisolone therapy speeds recovery but does not improve the final outcome. For patients judged to be at high risk of developing multiple sclerosis, immune prophylaxis with beta-interferon or glatiramer acetate is recommended.

MalaCards based summary : Optic Neuritis is related to autoimmune optic neuritis and neuromyelitis optica, and has symptoms including eye manifestations An important gene associated with Optic Neuritis is AQP4 (Aquaporin 4), and among its related pathways/superpathways are Toxoplasmosis and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Bevacizumab and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include eye, brain and testes, and related phenotypes are behavior/neurological and hematopoietic system

Disease Ontology : 12 An optic nerve disease that results in inflammation located in optic nerve which may cause a complete or partial loss of vision.

NIH Rare Diseases : 53 Optic neuritis is inflammation of the optic nerve, the nerve that carries the visual signal from the eye to the brain. The condition may cause sudden, reduced vision in the affected eye(s). While the cause of optic neuritis is unknown, it has been associated with autoimmune diseases, infections, multiple sclerosis, drug toxicity and deficiency of vitamin B-12. Vision often returns to normal within 2-3 weeks without treatment. In some cases, corticosteroids are given to speed recovery. If known, the underlying cause should be treated.

Wikipedia : 75 Optic neuritis is a demyelinating inflammation of the optic nerve. It is also known as optic papillitis... more...

Related Diseases for Optic Neuritis

Diseases in the Optic Neuritis family:

Autoimmune Optic Neuritis

Diseases related to Optic Neuritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 544)
# Related Disease Score Top Affiliating Genes
1 autoimmune optic neuritis 33.5 MOG MBP CNTF AQP4
2 neuromyelitis optica 33.2 MOG MBP HLA-DRB1 AQP4
3 optic nerve disease 32.4 MT-ND5 MT-ND4 MOG MBP AQP4
4 neuroretinitis 31.5 MOG AQP4
5 acute retrobulbar neuritis 31.5 MT-ND4 MBP
6 allergic encephalomyelitis 31.5 PLP1 MOG MBP
7 transverse myelitis 31.2 TNF MBP AQP4
8 myelitis 31.0 TNF MOG MBP AQP4
9 encephalitis 31.0 MOG CCR5 AQP4
10 pediatric multiple sclerosis 30.9 MOG HLA-DRB1
11 rubella 30.9 TNF MOG HLA-DRB1
12 leber optic atrophy 30.9 MT-ND5 MT-ND4
13 kearns-sayre syndrome 30.8 MT-ND5 MT-ND4 MAG
14 panencephalitis, subacute sclerosing 30.8 MOG MBP
15 relapsing-remitting multiple sclerosis 30.7 TNF MOG MBP AQP4
16 autoimmune disease 30.7 TNF MOG MBP HLA-DRB1
17 miller fisher syndrome 30.7 TNF MAG
18 cytomegalovirus retinitis 30.6 TNF CCR5
19 internuclear ophthalmoplegia 30.6 MOG MBP AQP4
20 sarcoidosis 1 30.4 TNF LTA HLA-DRB1
21 neuritis 30.3 TNF MPZ MOG MBP MAG AQP4
22 guillain-barre syndrome 30.1 TNF MPZ MBP
23 chronic inflammatory demyelinating polyradiculoneuropathy 30.1 MPZ HLA-DRB1
24 congenital hydrocephalus 30.0 TNF MBP
25 juvenile rheumatoid arthritis 30.0 TNF LTA HLA-DRB1
26 narcolepsy 29.9 TNF MOG HLA-DRB1
27 panuveitis 29.9 TNF HLA-DRB1
28 demyelinating disease 29.8 TNF PLP1 MOG MBP MAG AQP4
29 nervous system disease 29.8 TNF MOG MBP AQP4
30 oligoarticular juvenile idiopathic arthritis 29.8 TNF HLA-DRB1 CCR5
31 acute disseminated encephalomyelitis 29.8 MPZ MOG MBP HLA-DRB1 AQP4
32 polyneuropathy 29.8 MPZ MBP MAG
33 psoriatic arthritis 29.5 TNF LTA HLA-DRB1
34 wallerian degeneration 29.3 MPZ MAG CNTF
35 polyradiculoneuropathy 29.1 MPZ MBP MAG HLA-DRB1
36 primary progressive multiple sclerosis 29.1 TNF PLP1 MOG MBP HLA-DRB1
37 central nervous system disease 27.9 TNF PLP1 MOG MBP CNTF CCR5
38 charcot-marie-tooth disease 27.9 PLP1 MPZ MBP MAG CNTF
39 peripheral nervous system disease 27.9 TNF MT-ND4 MPZ MOG MBP MAG
40 multiple sclerosis 27.0 TNF PLP1 MPZ MOG MBP MAG
41 isolated optic neuritis 12.5
42 chronic relapsing inflammatory optic neuropathy 12.2
43 nutritional optic neuropathy 11.7
44 neuropathy 10.7
45 neuromyelitis optica spectrum disorder 10.7
46 scotoma 10.6
47 yemenite deaf-blind hypopigmentation syndrome 10.6
48 optic papillitis 10.6
49 measles 10.6
50 lupus erythematosus 10.6

Comorbidity relations with Optic Neuritis via Phenotypic Disease Network (PDN):


Hypertension, Essential Temporal Arteritis

Graphical network of the top 20 diseases related to Optic Neuritis:



Diseases related to Optic Neuritis

Symptoms & Phenotypes for Optic Neuritis

UMLS symptoms related to Optic Neuritis:


eye manifestations

MGI Mouse Phenotypes related to Optic Neuritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.07 AQP4 CCR5 CNTF LTA MAG MBP
2 hematopoietic system MP:0005397 10.02 AQP4 CCR5 CNTF LTA MAG MBP
3 homeostasis/metabolism MP:0005376 9.91 AQP4 CCR5 CNTF LTA MAG MBP
4 immune system MP:0005387 9.85 AQP4 CCR5 CNTF LTA MAG MBP
5 nervous system MP:0003631 9.65 AQP4 CCR5 CNTF LTA MAG MBP
6 vision/eye MP:0005391 9.17 AQP4 CCR5 LTA MBP MOG PLP1

Drugs & Therapeutics for Optic Neuritis

Drugs for Optic Neuritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 150)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4 216974-75-3
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Levodopa Approved Phase 4 59-92-7 6047
4
Carbidopa Approved Phase 4 28860-95-9 34359
5
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
6
4-Aminopyridine Approved Phase 4 504-24-5 1727
7
Idebenone Approved, Investigational Phase 4 58186-27-9
8
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
9
Choline Approved, Nutraceutical Phase 4 62-49-7 305
10 (T,G)-A-L Phase 4
11
Glatiramer Acetate Phase 4 147245-92-9 3081884
12 Angiogenesis Inhibitors Phase 4
13 Angiogenesis Modulating Agents Phase 4
14 Dopamine Agents Phase 4
15 Antiparkinson Agents Phase 4
16 Dopamine agonists Phase 4
17 Aromatic Amino Acid Decarboxylase Inhibitors Phase 4
18 Carbidopa, levodopa drug combination Phase 4
19 Nootropic Agents Phase 4
20 Cytidine Diphosphate Choline Phase 4
21 Potassium Channel Blockers Phase 4
22 Antioxidants Phase 4
23 Adrenocorticotropic Hormone Phase 4
24 Melanocyte-Stimulating Hormones Phase 4
25 beta-endorphin Phase 4
26 Phosphodiesterase Inhibitors Phase 4
27 Phosphodiesterase 5 Inhibitors Phase 4
28 Sildenafil Citrate Phase 4 171599-83-0
29 Vardenafil Dihydrochloride Phase 4
30
Curcumin Approved, Experimental, Investigational Phase 3 458-37-7 969516
31
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
32
Azathioprine Approved Phase 2, Phase 3 446-86-6 2265
33
Bosentan Approved, Investigational Phase 3 147536-97-8 104865
34
Interferon beta-1b Approved Phase 2, Phase 3 145155-23-3
35 Analgesics Phase 3
36 Analgesics, Non-Narcotic Phase 3
37 Anti-Inflammatory Agents, Non-Steroidal Phase 3
38 gamma-Globulins Phase 3
39 Immunoglobulins, Intravenous Phase 3
40 Rho(D) Immune Globulin Phase 3
41 Butylated Hydroxytoluene Phase 3
42 Mastic Phase 3
43 Endothelin Receptor Antagonists Phase 3
44 Hematinics Phase 3
45 Epoetin alfa Phase 3 113427-24-0
46 Pharmaceutical Solutions Phase 3
47 Central Nervous System Depressants Phase 3
48 Anesthetics Phase 3
49 Fingolimod Hydrochloride Phase 2, Phase 3
50 Antibodies Phase 3

Interventional clinical trials:

(show top 50) (show all 166)
# Name Status NCT ID Phase Drugs
1 A Multicenter Longitudinal Cross-sectional Pilot Study, to Compare RNFL Thickness Measured by OCT After Treatment With Glatiramer or After no Treatment in Patients With CIS With or Without Optic Neuritis or With Early RRMS Unknown status NCT00910598 Phase 4 glatiramer acetate
2 Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans Completed NCT00312325 Phase 4 Prednisolone
3 Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy Completed NCT00432393 Phase 4 levodopa-carbidopa
4 Dalfampridine Treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Completed NCT01975324 Phase 4 dalfampridine;Placebo
5 Controlled High-risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurologic Surveillance (CHAMPIONS10) Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
6 Phase 4 Study of Evaluation of Neural Conduction Along the Visual Pathways Before and After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases Completed NCT00404729 Phase 4 Cytidine-5’-diphosphocholine (Citicoline)
7 Use of Bevacizumab in Trabeculectomy Surgery. A Prospective, 2 Centre, Randomized, Controlled Trial Completed NCT01166594 Phase 4 Bevacizumab;Control
8 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet
9 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Recruiting NCT01838174 Phase 4 ACTHAR Gel (ACTH);IV methylprednisolone (steroids)
10 Short and Long Term Fampridine Treatment in Persons With Multiple Sclerosis: Cognitive and Motor Performances Recruiting NCT02849782 Phase 4 Fampridine
11 External Natural History Controlled, Open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment With Raxone® in Leber's Hereditary Optic Neuropathy (LHON) Active, not recruiting NCT02774005 Phase 4 Idebenone
12 Prospective Case Crossover Study to Assess Whether PDE5 Inhibitor Exposure in Men Increases the Risk for the Development of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Terminated NCT00867815 Phase 4 Diagnostic procedures
13 Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis Terminated NCT00854750 Phase 4 ACTHAR;ACTHAR;ACTHAR;ACTHAR
14 Optical Coherence Tomography as a Measure of Neuroprotection in Patients With Relapsing-Remitting Multiple Sclerosis Receiving Natalizumab or Interferon Beta-1a Withdrawn NCT00771043 Phase 4 TYSABRI and AVONEX
15 An Open Label Pilot Study of Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event: Comparison With CHAMPS Results. Withdrawn NCT00037115 Phase 4 interferon beta 1a;methotrexate;methylprednisolone
16 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: a Pivotal Randomized Double Masked Placebo Controlled Study Unknown status NCT02220244 Phase 3 MD1003 100mg capsule
17 Optic Neuritis Treatment Trial (ONTT) Unknown status NCT00000146 Phase 3 Methylprednisolone;Prednisone
18 Simvastatin Treatment of Patients With Acut Optic Neuritis. A Doubleblind, Randomized and Placebo Controlled Fase III Trial Unknown status NCT00261326 Phase 3 simvastatin;placebo
19 Retrobulbar Triamcinolone Acetonide Injection in the Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy Unknown status NCT02329288 Phase 3 Triamcinolone Acetonide;placebo
20 The Effect of High Dose Steroid and Normobaric Oxygen Therapy on Recent Onset Non-arteritic Anterior Ischemic Optic Neuropathy(NAION); a Randomized Clinical Trial Unknown status NCT02439866 Phase 3 placebo;Intravenous methylprednisolone;normobaric oxygen with face mask
21 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON) Completed NCT00856635 Phase 3 Glatiramer Acetate;placebo
22 Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis Completed NCT01337986 Phase 2, Phase 3 Dalfampridine/Placebo;Placebo/Dalfampridine
23 Recovery of Demyelinating Optic Neuritis After Treatment With Equivalent High Doses of Oral vs. Intravenous Corticosteroids: a Randomized Single Blinded Clinical Trial Completed NCT01524250 Phase 2, Phase 3 corticosteroids;corticosteroids
24 Intravenous Immunoglobulin Therapy in Optic Neuritis Completed NCT00000117 Phase 3 Immunoglobulin
25 Paraorbital-occipital Alternating Electric Current Stimulation in Patients With Optic Neuropathy Completed NCT01282827 Phase 2, Phase 3
26 A Randomized, Double-blind, Placebo-controlled Trial of Curcumin in Leber's Hereditary Optic Neuropathy (LHON) Completed NCT00528151 Phase 3 curcumin
27 Comparison of Annual Relapse Rate, Expanded Disability Status Scale, and Side Effects Between Azathioprine and Rituximab in Patients With Neuromyelitis Optica Spectrum Disorders Completed NCT03002038 Phase 2, Phase 3 Azathioprine;Rituximab
28 Ischemic Optic Neuropathy Decompression Trial (IONDT) Completed NCT00000127 Phase 3
29 Effects of Dalfampridine on Cognition in Multiple Sclerosis Completed NCT02006160 Phase 2, Phase 3 dalfampridine;placebo
30 A Double-Masked Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Participants With Previous NAION Recruiting NCT03547206 Phase 3 RPh201
31 Traumatic Optic Neuropathy Treatment Trial 2; Efficacy of Different Doses of Erythropoietin. A Multicenter, Double Blind RCT Recruiting NCT03308448 Phase 3 Recombinant human erythropoietin
32 Effect of Bosentan in Patients With Non Arteritic Ischemic Optic Neuropathy Recruiting NCT02377271 Phase 3 bosentan;placebo
33 Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial Active, not recruiting NCT01962571 Phase 3 Erythropoietin alfa;Placebo
34 A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO) Active, not recruiting NCT02003144 Phase 3
35 Erythropoietin in Methanol Associated Optic Neuropathy Active, not recruiting NCT02376881 Phase 3 Erythropoietin
36 Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected With G11778A ND4 Leber Hereditary Optic Neuropathy for Up to One Year Active, not recruiting NCT03293524 Phase 3 Placebo
37 Safety and Efficacy Study of Gene Therapy for The Treatment of Leber's Hereditary Optic Neuropathy Active, not recruiting NCT03153293 Phase 2, Phase 3 rAAV2-ND4
38 Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Recovery After Optic Neuritis Terminated NCT01647880 Phase 2, Phase 3 Verum arm receiving Gilenya®;Active Comparator receiving Extavia®
39 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO) Terminated NCT01892345 Phase 3 Eculizumab;Placebo
40 A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Terminated NCT02341560 Phase 2, Phase 3 QPI-1007 Injection - 1.5 mg;QPI-1007 Injection - 3.0 mg
41 Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON) Withdrawn NCT01495715 Phase 3 Idebenone;Placebo
42 The Investigation Effect of Vitamin D on Retinal Changes in Patient With Optic Neuritis by Optic Coherence Tomography Unknown status NCT01465893 Phase 2 Vitamin D;Vitamin D withheld
43 A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis Unknown status NCT01879527 Phase 2 Amiloride hydrochlorothiazide;Sugar pill
44 Trial of Cyclosporine in the Acute Phase of Leber Hereditary Optic Neuropathy Unknown status NCT02176733 Phase 2 cyclosporine
45 A Randomised, Double-blind, Placebo-controlled Study of AIMSPRO in Treating Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Unknown status NCT01228396 Phase 2 Hyperimmune caprine serum against HIV lysate
46 Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
47 Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo in Acute Nonarteritic Anterior Ischemic Optic Neuropathy Unknown status NCT01330524 Phase 1, Phase 2 Avastin and Triamcinolone
48 Intravitreal Bevacizumab for Treatment of the Second Eye With Non-Arteritic Ischemic Optic Neuropathy Unknown status NCT00813059 Phase 2 Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)
49 Hyperbaric Oxygen Treatment of Mandibular Osteoradionecrosis. A Randomized Clinical Study Unknown status NCT00760682 Phase 2
50 A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With First Episode of Acute Optic Neuritis Completed NCT01721161 Phase 2 Placebo

Search NIH Clinical Center for Optic Neuritis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Corticotropin
Cortisone acetate
Dexamethasone
Hydrocortisone
Methylprednisolone
Prednisolone
Prednisone
Tetracosactide

Cochrane evidence based reviews: optic neuritis

Genetic Tests for Optic Neuritis

Anatomical Context for Optic Neuritis

MalaCards organs/tissues related to Optic Neuritis:

41
Eye, Brain, Testes, Retina, Spinal Cord, T Cells, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Optic Neuritis:

19
Optic Nerve Which May Cause A Complete

Publications for Optic Neuritis

Articles related to Optic Neuritis:

(show top 50) (show all 5223)
# Title Authors PMID Year
1
Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. 9 38
20019228 2010
2
Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. 9 38
19917985 2009
3
Association of the HLA-DPB1*0501 allele with anti-aquaporin-4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders. 9 38
19140826 2009
4
Neuromyelitis optica pathogenesis and aquaporin 4. 9 38
18510734 2008
5
A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica. 9 38
18509235 2008
6
Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. 9 38
12838519 2003
7
Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. 9 38
12732654 2003
8
Multiple MAG peptides are recognized by circulating T and B lymphocytes in polyneuropathy and multiple sclerosis. 9 38
11985632 2002
9
Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD1a. 9 38
10618693 1999
10
Augmented expression of tumour necrosis factor-alpha and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis. 9 38
8624683 1996
11
Acute optic neuritis: myelin basic protein and proteolipid protein antibodies, affinity, and the HLA system. 9 38
8526468 1995
12
PCR typing of two short tandem repeat (STR) structures upstreams of the human myelin basic protein (MBP) gene; the genetic susceptibility in multiple sclerosis and monosymptomatic idiopathic optic neuritis in Danes. 9 38
9345452 1995
13
Increased mRNA expression of IL-10 in mononuclear cells in multiple sclerosis and optic neuritis. 9 38
7532318 1995
14
Optic neuritis and multiple sclerosis: the T cell repertoires to myelin proteins and MBP peptides change with time. 9 38
7524258 1994
15
Autoimmune T cell repertoire in optic neuritis and multiple sclerosis: T cells recognising multiple myelin proteins are accumulated in cerebrospinal fluid. 9 38
7515411 1994
16
Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis. 9 38
7510098 1994
17
Relative frequency of autoantibodies to myelin basic protein and proteolipid protein in optic neuritis and multiple sclerosis cerebrospinal fluid. 9 38
7510787 1994
18
Optic neuritis is associated with myelin basic protein and proteolipid protein reactive cells producing interferon-gamma, interleukin-4 and transforming growth factor-beta. 9 38
7507500 1994
19
Optic neuritis and multiple sclerosis: anti-MBP and anti-MBP peptide antibody-secreting cells are accumulated in CSF. 9 38
7513391 1993
20
T cells recognizing multiple peptides of myelin basic protein are found in blood and enriched in cerebrospinal fluid in optic neuritis and multiple sclerosis. 9 38
7680141 1993
21
Acute optic neuritis associated with immunization with the CNS myelin proteolipid protein. 9 38
1373123 1992
22
A comparative study on clinical features of anterior ischemic optic neuropathy and idiopathic optic neuritis. 38
30784250 2019
23
Eyes are mirror of the brain: comparison of multiple sclerosis patients and healthy controls using OCT. 38
30696321 2019
24
Inflammatory Reaction Secondary to Immune Checkpoint Inhibitor Therapy Mimicking a Post-Operative Brain Abscess. 38
31203078 2019
25
Feline Ocular Mycobacteriosis: Clinical Presentation, Histopathological Features, and Outcome. 38
31132943 2019
26
Ischemic Optic Neuropathy Secondary to Intravascular Lymphoma. 38
30531633 2019
27
Optical Coherence Tomography Angiography of a Pale Optic Disc in Demyelinating Optic Neuritis and Ischemic Optic Neuropathy. 38
30893268 2019
28
Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up. 38
31118222 2019
29
Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. 38
31136907 2019
30
Uveitis and optic perineuritis in the context of myelin oligodendrocyte glycoprotein antibody seropositivity. 38
30748058 2019
31
Accuracy of machine learning for differentiation between optic neuropathies and pseudopapilledema. 38
31399077 2019
32
Ultrasound-Assisted Diagnosis of Optic Neuritis in the Emergency Department: A Case Report. 38
31253461 2019
33
Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography. 38
31392924 2019
34
Retinal and optic nerve degeneration in liver X receptor β knockout mice. 38
31371497 2019
35
Efficacy and safety of fractionated conformal radiation therapy in acromegaly: a long-term follow-up study. 38
31098940 2019
36
Ultrasound and optic neuritis. 38
30744912 2019
37
Update on pediatric optic neuritis. 38
31433309 2019
38
Optic Neuritis In the Era of Biomarkers. 38
31425702 2019
39
Sleep disturbance and cognitive decline in multiple sclerosis patients with isolated optic neuritis as the first demyelinating event. 38
31432354 2019
40
Ultrasound optic nerve sheath diameter measurement in optic neuritis. 38
30683469 2019
41
A new association: acute macular neuroretinopathy in acute optic neuritis. 38
30761755 2019
42
Acute Optic Neuritis Diagnosed by Bedside Ultrasound in an Emergency Department. 38
31229301 2019
43
The clinical spectrum and prognosis of idiopathic acute optic neuritis: A longitudinal study in Southern Finland. 38
31401426 2019
44
Dexras1 Deletion and Iron Chelation Promote Neuroprotection in Experimental Optic Neuritis. 38
31406150 2019
45
MRI of acute optic neuritis (ON) at the first episode: Can we predict the visual outcome and the development of multiple sclerosis (MS)? 38
31435862 2019
46
The swollen optic nerve: an approach to diagnosis and management. 38
31196885 2019
47
The clinical spectrum of anti-MOG associated acquired demyelinating disorders: Three case-reports. 38
31152967 2019
48
Clinical Characteristics of Patients With Neuromyelitis Optica Spectrum Disorders With Early Onset. 38
31012355 2019
49
Linezolid interruption in patients with fluoroquinolone-resistant tuberculosis receiving a bedaquiline-based treatment regimen. 38
31100421 2019
50
Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study. 38
31345223 2019

Variations for Optic Neuritis

ClinVar genetic disease variations for Optic Neuritis:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 MT-ND4 NC_012920.1: m.11443A> C single nucleotide variant Uncertain significance rs1556423952 MT:11443-11443 MT:11443-11443

Expression for Optic Neuritis

Search GEO for disease gene expression data for Optic Neuritis.

Pathways for Optic Neuritis

Pathways related to Optic Neuritis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.82 TNF HLA-DRB1 CCR5
2 11.64 TNF PLP1 AQP4
3 11.5 MPZ MAG HLA-DRB1
4 11.34 TNF MBP MAG AQP4
5 10.78 TNF HLA-DRB1
6 9.7 PLP1 MBP MAG

GO Terms for Optic Neuritis

Cellular components related to Optic Neuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 9.26 PLP1 MPZ MBP MAG
2 compact myelin GO:0043218 9.16 MBP MAG
3 external side of plasma membrane GO:0009897 9.02 TNF MOG HLA-DRB1 CCR5 AQP4
4 integral component of membrane GO:0016021 10.07 TNF PLP1 MT-ND5 MT-ND4 MPZ MOG
5 membrane GO:0016020 10.03 TNF PLP1 MT-ND5 MT-ND4 MPZ MOG
6 plasma membrane GO:0005886 10.02 TNF PLP1 MPZ MOG MBP MAG

Biological processes related to Optic Neuritis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.72 TNF MBP LTA HLA-DRB1 CCR5
2 response to hypoxia GO:0001666 9.69 MT-ND5 MT-ND4 LTA
3 positive regulation of glial cell proliferation GO:0060252 9.49 TNF LTA
4 negative regulation of growth of symbiont in host GO:0044130 9.48 TNF LTA
5 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 9.46 MPZ MAG
6 central nervous system myelination GO:0022010 9.43 PLP1 MAG
7 astrocyte activation GO:0048143 9.4 TNF CNTF
8 ATP synthesis coupled electron transport GO:0042773 9.37 MT-ND5 MT-ND4
9 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.26 TNF LTA
10 axon ensheathment GO:0008366 9.16 PLP1 MBP
11 myelination GO:0042552 9.13 PLP1 MPZ MBP
12 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 8.62 TNF LTA

Molecular functions related to Optic Neuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.5 TNF LTA CNTF
2 tumor necrosis factor receptor binding GO:0005164 9.26 TNF LTA
3 NADH dehydrogenase activity GO:0003954 9.16 MT-ND5 MT-ND4
4 structural constituent of myelin sheath GO:0019911 8.96 PLP1 MBP
5 virus receptor activity GO:0001618 8.8 MOG HLA-DRB1 CCR5

Sources for Optic Neuritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....